Loading...
•
Sep 30
Ginkgo Bioworks Q3 2025 Earnings Report
Ginkgo Bioworks' third quarter 2025 financial results were announced, highlighting a decrease in total revenue and an increased net loss compared to the previous year, alongside a significant reduction in cash and cash equivalents.
Key Takeaways
Ginkgo Bioworks reported a challenging third quarter in 2025, with total revenue decreasing to $38.837 million from $89.046 million in the prior year. The company experienced a net loss of $80.755 million, an increase from $56.403 million in Q3 2024. Cash and cash equivalents saw a substantial decline, ending the quarter at $111.065 million compared to $561.572 million at the end of 2024.
Total revenue for Q3 2025 was $38.837 million, a significant decrease from $89.046 million in Q3 2024.
The company reported a net loss of $80.755 million for the quarter, compared to a net loss of $56.403 million in the same period last year.
Operating loss widened to $90.017 million in Q3 2025 from $55.204 million in Q3 2024.
Cash and cash equivalents decreased substantially to $111.065 million as of September 30, 2025, from $561.572 million at December 31, 2024.
Ginkgo Bioworks
Ginkgo Bioworks
Ginkgo Bioworks Revenue by Segment
Revenue by Segment
Cell Engineering Revenue
CapyFin.comBiosecurity Service Revenue
CapyFin.com Forward Guidance
The report mentions a discussion on Ginkgo's outlook during the conference call, but specific forward-looking financial guidance details are not provided in the given text.